(8) assessed high-dose bolus interleukin-2 (IL-2) given postoperatively in patients with high-risk renal cell carcinoma defined as completely resected locally advanced (T3b–4 or N1–3) or metastatic (M1) disease. The gene discussed is IL2; the disease is renal cell carcinoma.